Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Debio-025
2. Meala(3)etval(4)-cyclosporin
3. Unil 025
4. Unil-025
5. Unil025
1. Debio-025
2. 254435-95-5
3. Debio 025
4. Unil 025
5. Unil-025
6. Deb-025
7. Deb025
8. (d-meala)3-(etval)4-csa
9. Vbp9099aa6
10. Chembl1651956
11. Deb 025
12. Alisporivir (usan)
13. Alisporivir [usan]
14. (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r,e)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
15. Cyclo(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-(2s,3r,4r,6e)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl-(2s)-2-aminobutanoyl-n-methyl-d-alanyl-n-ethyl-l-valyl-l-valyl-n-methyl-l-leucyl)
16. Alisporivir [inn]
17. Alisporivir [usan:inn]
18. Unii-vbp9099aa6
19. Unil025
20. Meala(3)etval(4)-cyclosporin
21. Alisporivir [who-dd]
22. Debio-025;deb-025
23. Schembl6850787
24. Chebi:149837
25. Dtxsid401027752
26. Bdbm50339127
27. De-025
28. Cs-7501
29. Db12139
30. Hy-12559
31. D10087
32. Q4727236
33. (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r)-1-hydroxy-2-methylhex-4-enyl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
34. (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-((1r,2r,e)-1-hydroxy-2-methylhex-4-enyl)-6,9,18-triisobutyl-3,21,24-triisopropyl-1,4,7,10,12,15,19,27,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
35. (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tris(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecone
36. (3s,6s,9s,12r,15s,18s,21s,24s,27r,30s,33s)-25,30-diethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
| Molecular Weight | 1216.6 g/mol |
|---|---|
| Molecular Formula | C63H113N11O12 |
| XLogP3 | 7.9 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 15 |
| Exact Mass | 1215.85701808 g/mol |
| Monoisotopic Mass | 1215.85701808 g/mol |
| Topological Polar Surface Area | 279 Ų |
| Heavy Atom Count | 86 |
| Formal Charge | 0 |
| Complexity | 2360 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 13 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of chronic hepatitis C
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
66
PharmaCompass offers a list of Alisporivir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Alisporivir manufacturer or Alisporivir supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Alisporivir manufacturer or Alisporivir supplier.
PharmaCompass also assists you with knowing the Alisporivir API Price utilized in the formulation of products. Alisporivir API Price is not always fixed or binding as the Alisporivir Price is obtained through a variety of data sources. The Alisporivir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Alisporivir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Alisporivir, including repackagers and relabelers. The FDA regulates Alisporivir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Alisporivir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Alisporivir supplier is an individual or a company that provides Alisporivir active pharmaceutical ingredient (API) or Alisporivir finished formulations upon request. The Alisporivir suppliers may include Alisporivir API manufacturers, exporters, distributors and traders.
Alisporivir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Alisporivir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Alisporivir GMP manufacturer or Alisporivir GMP API supplier for your needs.
A Alisporivir CoA (Certificate of Analysis) is a formal document that attests to Alisporivir's compliance with Alisporivir specifications and serves as a tool for batch-level quality control.
Alisporivir CoA mostly includes findings from lab analyses of a specific batch. For each Alisporivir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Alisporivir may be tested according to a variety of international standards, such as European Pharmacopoeia (Alisporivir EP), Alisporivir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Alisporivir USP).
